Development of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules.
OBJECTIVE
To study, diffusion through mucus (3D model) of different formulations of paclitaxel loaded lipid nanocapsules (Ptx-LNCs), to interpret the results in the light of LNC behavior at air-mucus interface (2D model).


METHODS
LNC surface properties were modified with chitosan or poly(ethylene glycol) (PEG) coatings of different size (PEG 2,000 to 5,000 Da) and surface charges. LNC diffusion through 446 μm pig intestinal mucus layer was studied using Transwell(®). LNCs were spread at the air-water-mucus interface then interfacial pressure and area changes were monitored and the efficiency of triglyceride (TG) inclusion was determined.


RESULTS
Ptx-LNCs of surface charges ranging from -35.7 to +25.3 mV were obtained with sizes between 56.2 and 75.1 nm. The diffusion of paclitaxel in mucus was improved after encapsulation in neutral or positively charged particles (p < 0.05 vs Taxol(®)). No significative difference was observed in the 2,000-5,000 PEG length for diffusion both on the 2D or 3D models. On 2D model positive or neutral LNCs interacted less with mucus. Highest efficiency of TG inclusion was observed for particles with smallest PEG length.


CONCLUSIONS
The results obtained with 2D and 3D model allowed us to select the best candidates for in vivo studies (neutral or positive LNCs with smaller PEG length).
INSERM U1066 MINT «Micro et nanomédecines biomimétiques», LUNAM Université, 49100, Angers, France.
Anne-Claire
AC
Groo
Kristina
K
Mircheva
Jérôme
J
Bejaud
Caroline
C
Ailhas
Ivan
I
Panaiotov
Patrick
P
Saulnier
Tzvetanka
T
Ivanova
Frederic
F
Lagarce
D000284:Administration, Oral; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D048271:Chitosan / Q000737:chemistry / Q000378:metabolism; D004058:Diffusion; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism; D008954:Models, Biological; D009093:Mucus / Q000378:metabolism*; D053769:Nanocapsules / Q000737:chemistry*; D017239:Paclitaxel / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry / Q000378:metabolism; D013499:Surface Properties; D013552:Swine
D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D053769:Nanocapsules; D011092:Polyethylene Glycols; D048271:Chitosan; D017239:Paclitaxel